Mechanisms of Action of the Herba Salviae Chinensis-Fructus Akebiae Pair in the Treatment of Non-small Cell Lung Cancer based on a Network Pharmacology Study

Authors

  • Guomin Dong Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Zhiyun Zhang Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Qian Ge Xi'an Medical University, Xi'an 710021, Shaanxi, China
  • Pengyu Han Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Jian Jiang Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Suoni Li Shaanxi Provincial Cancer Hospital, Xi'an 710000, Shaanxi, China
  • Jiequn Ma Shaanxi Provincial Cancer Hospital, Xi'an 710000, Shaanxi, China
  • Jie Bai Shaanxi Provincial Cancer Hospital, Xi'an 710000, Shaanxi, China
  • Yafen Qi Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
  • Zheng Zhao Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China; Shaanxi Provincial Cancer Hospital, Xi'an 710000, Shaanxi, China

DOI:

https://doi.org/10.53469/jcmp.2024.06(09).24

Keywords:

Herba Salviae Chinensis, Fructus Akebiae, Non-small cell lung cancer, Network pharmacology

Abstract

Objective: To study the active ingredients and mechanism of action of "Herba Salviae Chinensis-Fructus Akebiae" drug pair in the treatment of non-small cell lung cancer (NSCLC) by using network pharmacology to provide theoretical basis for clinical application. Methods: The TCMSP (Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform) was used to obtain the active ingredients and targets of "Herba Salviae Chinensis-Fructus Akebiae", and the results were analyzed by the Genecard (https://genecard, org/) database, the Online Mendelian Inheritance Network (OMI), the Genecard database, the Genecard database, and the Online Mendelian Inheritance Network. We searched the Genecard (https://genecard, org/) database and the Online Mendelian Inheritance in Man (OMIM) database (http://omim. org/) for non-small cell lung cancer (NSCLC) disease targets by selecting "NSCLC" as a keyword, and then obtained the results of the "Herba Salviae Chinensis-Fructus Akebiae" drug pair by using venn. We used venn to obtain the intersecting targets of the drug pair "Herba Salviae Chinensis-Fructus Akebiae" and NSCLC, and then used the STRING database and Cytoscape to construct a common target visualization network diagram. The gene (GO) enrichment analysis and KEGG enrichment analysis were realized with the help of metascape database and Microbiology platform. Results: Five active ingredients of Ishiminokan-Precipitant were obtained, and 3695 non-small cell lung cancer targets and 123 common targets were obtained. GO analysis showed that the process of GO enrichment was mainly related to the regulation of responses to inorganic substances, transcriptional regulatory complexes, cytokine receptor binding, etc. KEGG enrichment showed that the process of KEGG enrichment was mainly through Pathways in Cancer, ILRT, and cytokine receptor binding. KEGG enrichment showed that KEGG mainly exerted anti-cancer effects through pathways in cancer and IL-17 signaling pathway. Conclusion: Using the method of network pharmacology, it is proved that the drug pair "Herba Salviae Chinensis-Fructus Akebiae" can exert therapeutic effects on NSCLC through multi-components, multi-targets, and multi-pathways, and provides the theoretical basis for the clinical application.

References

Bray F, Laversanne M, Sung H, et al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.

H.M. Abdelaziz, M. Gaber, M.M. Abd-Elwakil, et al.. Elzoghby Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates J. Control Release, 269 (2018), pp. 374-392.

LING C Q, YUE Q, CHEN L. Three advantages of using traditional Chinese medicine to prevent and treat tumor[J]. J Integr Med, 2014, 12(4):331-335.

Yang Wenjing, Zhang Ganlin, Yang Guowang. Exploration of anti-tumor therapeutic mechanism by activating blood circulation and removing blood stasis [J]. Liaoning Journal of Chinese Medicine, 2019, 46(11):2311-2314.

WANG Yanhong, GUAN Feng, WANG Ri. Progress of research on Chinese medicine Shihmianuan [J]. Chinese Pharmacy, 2006(24): 1909 -1910.

ZHOU Li, LI Chen, CAO Fengjun, et al. Anti-cancer Chinese medicine Prevotella / Yan Cui: Herbal variation and resource distribution [J]. Journal of Chinese Medicine Clinics, 2019, 31(5):799 -803.

Jiao Minghao, Qi Yuanfu. Introduction of Prof. Qi Yuanfu's experience in treating lung cancer by using medicinal pairs[J]. Yunnan Journal of Traditional Chinese Medicine, 2020, 41(11):9-12.

N. Wathoni, L.E. Puluhulawa, I.M. Joni, et al.. Gozali Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer Drug Deliv., 29 (1) (2022), pp. 2959-2970

L. E. MathieuLN, A.K. Sinha, P.S. Mishra-Kalyani, et al.. Singh FDA approval summary: atezolizumab as adjuvant treatment following surgical resection and platinum-based chemotherapy for stage II to IIIA NSCLC Clin. Cancer Res, 29 (16) (2023), pp. 2973-2978

X. Zhu, Z. Yu, L. Feng, et al.. Zheng Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer Carbohydr. Polym., 268 (2021), Article 118237

Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023 Dec 31;169:115891.

You Jiafeng, Yu Mingwei, Shang Beibei, et al. Effect of Zilongjin tablets on survival time of patients with middle and advanced non-small cell lung cancer[J]. Beijing Traditional Chinese Medicine, 2024, 43(03):250-255.

Lotfi N, Yousefi Z, Golabi M, et al.. The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update. Front Immunol. 2023 Feb 28;14:1077531.

Kashyap D, Garg VK, Tuli HS, et al.. Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules (2019) 9(5).

Izdebska M, Hałas-Wiśniewska M, Zielińska W, et al.. Lidocaine induces protective autophagy in rat C6 glioma cell line. Int J Oncol (2019) 54(3):1099–111.

Mukherjee A, Khuda-Bukhsh AR. Quercetin down-regulates IL-6/STAT-3 signals to induce mitochondrial-mediated apoptosis in a nonsmall- cell lung-cancer cell line, A549. J Pharmacopunct (2015) 18(1):19–26.

Sacks D, Baxter B, Campbell BCV, et al.. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke (2018) 13(6):612–32.

Chen Y, Yang Y, Wang N, et al.. β-Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1-regulated Wnt/β-catenin pathway. J Cell Mol Med. 2024 Feb;28(3):e18072.

Rashid ZA, Bardaweel SK. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment. Int J Mol Sci. 2023 Jul 28;24(15):12133.

Bhat AA, Thapa R, Afzal O, et al.. The pyroptotic role of Caspase-3/GSDME signalling pathway among various cancer: A Review. Int J Biol Macromol. 2023 Jul 1;242(Pt 2):124832.

Kaloni D, Diepstraten ST, Strasser A, et al.. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023 Feb;28(1-2):20-38.

Zheng W, Guo Y, Kahar A, et al.. RUNX1-induced upregulation of PTGS2 enhances cell growth, migration and invasion in colorectal cancer cells. Sci Rep. 2024 May 22;14(1):11670.

Lin Y, Sun N, Liu D, et al.. COX-2/PTGS2-targeted herbal-derived oligonucleotide drug HQi-sRNA-2 was effective in spontaneous mouse lung cancer model. IUBMB Life. 2024 Jul 25.

Lin XM, Li S, Zhou C, et al.. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. Int J Biochem Cell Biol. 2019 Nov;116:105610.

Zhang Y, Wang S, Hu H, et al.. A systematic study of HIF1A cofactors in hypoxic cancer cells. Sci Rep. 2022 Nov 8;12(1):18962.

Wu Q, You L, Nepovimova E, et al.. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022 Jun 3;15(1):77.

Chen Z, Ding C, Chen J, et al.. Pan-cancer analysis revealing the multidimensional expression and prognostic and immunologic roles of TGFB1 in cancer. J Int Med Res. 2024 Jan;52(1):3000605231221361.

Huangfu L, Li R, Huang Y, et al.. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023 Oct 11;8(1):402.

Manohar SM. At the Crossroads of TNF α Signaling and Cancer. Curr Mol Pharmacol. 2024; 17(1): e060923220758.

Zhang Z, Ma J, Li S, et al.. Integrating Network Pharmacology to Explore the Pharmacology Mechanisms of Meliae Cortex Against Hepatocellular Carcinoma [J]. Journal of Contemporary Medical Practice, 2024, 6(6):135-140.

Downloads

Published

2024-09-26

How to Cite

Dong, G., Zhang, Z., Ge, Q., Han, P., Jiang, J., Li, S., … Zhao, Z. (2024). Mechanisms of Action of the Herba Salviae Chinensis-Fructus Akebiae Pair in the Treatment of Non-small Cell Lung Cancer based on a Network Pharmacology Study. Journal of Contemporary Medical Practice, 6(9), 123–130. https://doi.org/10.53469/jcmp.2024.06(09).24

Issue

Vol. 6 No. 9 (2024): JCMP-Volume 6 Issue 9

Section

Articles

License

Copyright (c) 2024 Guomin Dong, Zhiyun Zhang, Qian Ge, Pengyu Han, Jian Jiang, Suoni Li, Jiequn Ma, Jie Bai, Yafen Qi, Zheng Zhao

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.